2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

2011;58;2703-2738; originally published online Nov 8, 2011; J. Am. Coll. Cardiol. W. Yancy Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, and Clyde Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Bernard J. Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Thoracic Surgeons Society for Cardiovascular Angiography and Interventions, and Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, of Thoracic Surgery, American Society of Echocardiography, American Society Developed in Collaboration With the American Association for Guidelines Cardiology Foundation/American Heart Association Task Force on Practice Cardiomyopathy: Executive Summary: A Report of the American College of 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic This information is current as of May 14, 2012 http://content.onlinejacc.org/cgi/content/full/58/25/2703 located on the World Wide Web at: The online version of this article, along with updated information and services, is

[1]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[2]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[3]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[4]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[5]  B. Maron,et al.  Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. , 2011, The American journal of cardiology.

[6]  Andrew S. Mugglin,et al.  Longevity of Sprint Fidelis Implantable Cardioverter-Defibrillator Leads and Risk Factors for Failure: Implications for Patient Management , 2011, Circulation.

[7]  J. Stockman.  Clinical Outcome and Phenotypic Expression in LAMP2 Cardiomyopathy , 2011 .

[8]  M. Cheitlin,et al.  Myocardial Scar Visualized by Cardiovascular Magnetic Resonance Imaging Predicts Major Adverse Events in Patients With Hypertrophic Cardiomyopathy , 2011 .

[9]  B. Gersh,et al.  Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[10]  B. Maron.  Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[11]  V. Dilsizian,et al.  Myocardial perfusion imaging in hypertrophic cardiomyopathy. , 2010, JACC. Cardiovascular imaging.

[12]  B. Maron,et al.  Novel hypertrophic cardiomyopathy phenotype: segmental hypertrophy isolated to the posterobasal left ventricular free wall. , 2010, The American journal of cardiology.

[13]  M. Maron,et al.  Survival After Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[14]  B. Maron,et al.  Prevalence and Clinical Significance of Aortic Root Dilation in Highly Trained Competitive Athletes , 2010, Circulation.

[15]  S. Colan,et al.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. , 2010, The New England journal of medicine.

[16]  Ross Arena,et al.  Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. , 2010, Circulation.

[17]  B. Maron,et al.  Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. , 2010, European heart journal.

[18]  Barry J Maron,et al.  Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. , 2010, The American journal of cardiology.

[19]  Edward P. Ficaro,et al.  Recommendations for reducing radiation exposure in myocardial perfusion imaging , 2010, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[20]  P. Serruys,et al.  Long-Term Outcome of Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy: A Word of Caution , 2010, Circulation. Heart failure.

[21]  B. Maron,et al.  Long-term clinical consequences of intense, uninterrupted endurance training in olympic athletes. , 2010, Journal of the American College of Cardiology.

[22]  W. Chung,et al.  Short Communication: The Cardiac Myosin Binding Protein C Arg502Trp Mutation: A Common Cause of Hypertrophic Cardiomyopathy , 2010, Circulation research.

[23]  Michael J Ackerman,et al.  Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.

[24]  S. Ommen,et al.  Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you. , 2010, Circulation. Cardiovascular interventions.

[25]  D. Atsma,et al.  The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. , 2010, European heart journal.

[26]  D. Simel,et al.  Meta-Analyses of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy: Comparative Rates of Overall Mortality and Sudden Cardiac Death After Treatment , 2010, Circulation. Cardiovascular interventions.

[27]  Michel Haissaguerre,et al.  Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[28]  S. Bernasconi,et al.  Update on age at menarche in Italy: toward the leveling off of the secular trend. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[29]  N. Smedira,et al.  Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[30]  P. Schlattmann,et al.  Meta-analysis: Noninvasive Coronary Angiography Using Computed Tomography Versus Magnetic Resonance Imaging , 2010, Annals of Internal Medicine.

[31]  H. Rakowski,et al.  Diastolic myocardial mechanics in hypertrophic cardiomyopathy. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[32]  B. Maron.  Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. , 2010, Circulation.

[33]  M. Sheppard,et al.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .

[34]  A. Tajik,et al.  Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[35]  R. Shephard.  Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2010 .

[36]  K. McBride,et al.  Parental Knowledge and Attitudes Toward Hypertrophic Cardiomyopathy Genetic Testing , 2010, Pediatric Cardiology.

[37]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[38]  William H. Maisel,et al.  Left atrial appendage occlusion--closure or just the beginning? , 2009, The New England journal of medicine.

[39]  F. T. ten Cate,et al.  Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. , 2009, European heart journal.

[40]  P. Lambiase,et al.  Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. , 2009, European heart journal.

[41]  Claire Duvernoy,et al.  Evaluation of Patients With Severe Symptomatic Aortic Stenosis Who Do Not Undergo Aortic Valve Replacement: The Potential Role of Subjectively Overestimated Operative Risk , 2009, Circulation. Cardiovascular quality and outcomes.

[42]  B. Maron.  Hypertrophic cardiomyopathy centers. , 2009, The American journal of cardiology.

[43]  R. Kwong,et al.  Clinical application of cardiac CMR. , 2009, Reviews in cardiovascular medicine.

[44]  E. Benjamin,et al.  ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiova , 2009, Journal of the American College of Cardiology.

[45]  Jianwen Wang,et al.  Delayed untwisting: the mechanistic link between dynamic obstruction and exercise tolerance in patients with hypertrophic obstructive cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[46]  M. Link,et al.  Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. , 2009, Circulation.

[47]  A. Wilde,et al.  Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. , 2009, Heart rhythm.

[48]  B. Maron,et al.  Distinguishing hypertrophic cardiomyopathy from athlete’s heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening , 2009, British Journal of Sports Medicine.

[49]  T. Sundt,et al.  What is the best surgical treatment for obstructive hypertrophic cardiomyopathy and degenerative mitral regurgitation? , 2009, The Annals of thoracic surgery.

[50]  G. Giannakoulas,et al.  Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.

[51]  Barry J Maron,et al.  The case for myocardial ischemia in hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[52]  B. Maron,et al.  Echocardiographic Strain Imaging to Assess Early and Late Consequences of Sarcomere Mutations in Hypertrophic Cardiomyopathy , 2009, Circulation. Cardiovascular genetics.

[53]  B. Gersh,et al.  Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. , 2009, Journal of the American College of Cardiology.

[54]  W. Manning,et al.  Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. , 2009, Journal of the American College of Cardiology.

[55]  J. Towbin,et al.  Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[56]  J. Hodges,et al.  Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. , 2009, Heart rhythm.

[57]  S. Ommen,et al.  Left Ventricular Outflow Tract Gradient Variability in Hypertrophic Cardiomyopathy , 2009, Clinical cardiology.

[58]  I. Palacios,et al.  Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.

[59]  G. Bonsel,et al.  Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: The patients' perspective , 2009, American journal of medical genetics. Part A.

[60]  E. Braunwald,et al.  The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[61]  D. Corrado,et al.  Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. , 2009, European heart journal.

[62]  Ana Morales,et al.  Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2009, Circulation. Heart failure.

[63]  M. Link,et al.  Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. , 2009, Heart rhythm.

[64]  N. Lakkis,et al.  Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. , 2009, European heart journal.

[65]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[66]  G. Bonsel,et al.  Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: A cross‐sectional cohort study , 2009, American journal of medical genetics. Part A.

[67]  C. Semsarian,et al.  Multiple Mutations in Genetic Cardiovascular Disease: A Marker of Disease Severity? , 2009, Circulation. Cardiovascular genetics.

[68]  B. Gersh,et al.  Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy , 2009, Heart.

[69]  L. Hougs,et al.  Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives , 2009, Human mutation.

[70]  B. Gersh,et al.  How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. , 2009, Circulation. Cardiovascular genetics.

[71]  A. Dipchand,et al.  Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[72]  Hypertrophic cardiomyopathy without hypertrophy: an emerging pre-clinical subgroup composed of genetically affected family members. , 2009, JACC. Cardiovascular imaging.

[73]  N. Smedira,et al.  Abnormally thickened papillary muscle resulting in dynamic left ventricular outflow tract obstruction: an unusual presentation of hypertrophic cardiomyopathy. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[74]  J. Veselka,et al.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective , 2009, Heart and Vessels.

[75]  B. Maron,et al.  Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. , 2008, Journal of the American College of Cardiology.

[76]  Scott D Flamm,et al.  Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[77]  M. Gold,et al.  Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[78]  M. Sherrid,et al.  Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up. , 2008, The Annals of thoracic surgery.

[79]  A. Kadish,et al.  Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. , 2008, Heart rhythm.

[80]  Jeroen J. Bax,et al.  Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. , 2008, JACC. Cardiovascular imaging.

[81]  A. Ralph-Edwards,et al.  Hypertrophic cardiomyopathy: current understanding and treatment objectives , 2008, Journal of Clinical Pathology.

[82]  W. Manning,et al.  Response to Letter Regarding Article, “Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy” , 2009 .

[83]  D. Callans.  Ablation of Atrial Fibrillation in the Setting of Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[84]  B. Gersh,et al.  Effect of septal ablation on myocardial relaxation and left atrial pressure in hypertrophic cardiomyopathy an invasive hemodynamic study. , 2008, JACC. Cardiovascular interventions.

[85]  S. Nagueh,et al.  Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. , 2008, JACC. Cardiovascular interventions.

[86]  S. Ommen,et al.  Substrate and Procedural Predictors of Outcomes After Catheter Ablation for Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[87]  B. Maron,et al.  Implantable Defibrillators and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[88]  Warren J Manning,et al.  Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy , 2008, Circulation. Heart failure.

[89]  Deborah H. Kwon,et al.  Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. , 2008, JACC. Cardiovascular interventions.

[90]  B. Gersh,et al.  Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2008, Circulation.

[91]  A. Tajik,et al.  Clinical and echocardiographic variables fail to predict response to dual-chamber pacing for hypertrophic cardiomyopathy. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[92]  Shemy Carasso,et al.  Systolic myocardial mechanics in hypertrophic cardiomyopathy: novel concepts and implications for clinical status. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[93]  Rachael,et al.  Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. , 2008, Mayo Clinic proceedings.

[94]  S. Antonarakis,et al.  A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy , 2008, Human mutation.

[95]  J. Ornato,et al.  ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2008, Heart rhythm.

[96]  Y. Jang,et al.  Incremental value of left ventricular diastolic function reserve index for predicting exercise capacity in patients with hypertrophic cardiomyopathy. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[97]  P. Serruys,et al.  Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. , 2008, The American journal of cardiology.

[98]  P. Lambiase,et al.  Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end‐stage hypertrophic cardiomyopathy , 2008, European journal of heart failure.

[99]  M. Vannan,et al.  Myocardial mechanics explains the time course of benefit for septal ethanol ablation for hypertrophic cardiomyopathy. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[100]  Heidi L Rehm,et al.  Shared genetic causes of cardiac hypertrophy in children and adults. , 2008, The New England journal of medicine.

[101]  W. Manning,et al.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[102]  L. Wann,et al.  ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 appropriateness criteria for stress echocardiography: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, , 2008, Journal of the American College of Cardiology.

[103]  S. Ommen,et al.  Myths about surgical myectomy: rumors of its death have been greatly exaggerated. , 2008, The American journal of cardiology.

[104]  W. Manning,et al.  Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[105]  S. Ommen,et al.  Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[106]  W. Roberts,et al.  Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. , 2008, The American journal of cardiology.

[107]  G. Boriani,et al.  Heart transplantation in hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[108]  P. Phongsavan,et al.  Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy , 2008, Genetics in Medicine.

[109]  G. Vlahakes,et al.  Management of Symptoms in Hypertrophic Cardiomyopathy , 2008, Circulation.

[110]  J. Seidman,et al.  Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics , 2007, Journal of cardiovascular electrophysiology.

[111]  A. Tajik,et al.  Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future , 2007, Heart.

[112]  N. Smedira,et al.  Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. , 2008, The Annals of thoracic surgery.

[113]  C. Stellbrink,et al.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience , 2008, Clinical Research in Cardiology.

[114]  H. Rakowski,et al.  Quantifying diastolic function in hypertrophic cardiomyopathy: the ongoing search for the holy grail. , 2007, Circulation.

[115]  S. Ommen,et al.  Evaluation of Left Ventricular Filling Pressures by Doppler Echocardiography in Patients With Hypertrophic Cardiomyopathy: Correlation With Direct Left Atrial Pressure Measurement at Cardiac Catheterization , 2007, Circulation.

[116]  S. Ommen,et al.  Septal myectomy after previous septal artery ablation in hypertrophic cardiomyopathy. , 2007, Mayo Clinic proceedings.

[117]  K. Smith,et al.  Depression, anxiety, and quality of life in patients with obstructive hypertrophic cardiomyopathy three months after alcohol septal ablation. , 2007, The American journal of cardiology.

[118]  A. Tajik,et al.  Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.

[119]  S. Ommen,et al.  Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? , 2007, Journal of the American College of Cardiology.

[120]  Mario J. Garcia,et al.  Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy , 2007, Heart.

[121]  Michael J Ackerman,et al.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.

[122]  I. Komuro,et al.  Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. , 2007, International journal of cardiology.

[123]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[124]  D. Fassbender,et al.  Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. , 2007, International journal of cardiology.

[125]  B. Maron.  Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy , 2007 .

[126]  F. Gaita,et al.  Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. , 2007, The American journal of cardiology.

[127]  Thomas Kleemann,et al.  Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators Over a Period of >10 Years , 2007, Circulation.

[128]  S. Colan,et al.  Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry , 2007, Circulation.

[129]  Y. Eshet,et al.  The prevalence and anatomical patterns of intramuscular coronary arteries: a coronary computed tomography angiographic study. , 2007, Journal of the American College of Cardiology.

[130]  A. Tajik,et al.  Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[131]  B. Maron.  Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. , 2007, Circulation.

[132]  J. Yagüe,et al.  Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[133]  I. Palacios,et al.  Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy , 2006, Heart.

[134]  B. Maron,et al.  Determinants for clinical diagnosis of hypertrophic cardiomyopathy. , 2006, The American journal of cardiology.

[135]  Samuel Wann,et al.  [Guidelines for the management of patients with atrial fibrillation. Executive summary]. , 2006, Revista espanola de cardiologia.

[136]  M. Link,et al.  Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2006, Circulation.

[137]  Bruce D Gelb,et al.  Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. , 2006, Human molecular genetics.

[138]  Barry J Maron,et al.  The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. , 2006, Circulation.

[139]  B. Maron,et al.  Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). , 2006, The American journal of cardiology.

[140]  B. Bembi,et al.  Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II , 2006, Human mutation.

[141]  S. Colan,et al.  Factors Associated With Establishing a Causal Diagnosis for Children With Cardiomyopathy , 2006, Pediatrics.

[142]  E. Gronda,et al.  Rationale and process: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[143]  I. Palacios,et al.  Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. , 2006, European Heart Journal.

[144]  P. Elliott,et al.  Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. , 2006, European heart journal.

[145]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[146]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.

[147]  W. Bamlet,et al.  Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis: The Detect Supraventricular Tachycardia Study , 2006, Circulation.

[148]  J. Veselka,et al.  Age-related hemodynamic and morphologic differences in patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[149]  A. Tajik,et al.  Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[150]  I. Palacios,et al.  Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. , 2006, The American journal of cardiology.

[151]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[152]  Michael J Ackerman,et al.  Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. , 2006, Mayo Clinic proceedings.

[153]  K. Serri,et al.  Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[154]  F. Girolami,et al.  Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[155]  M. Laakso,et al.  Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes. , 2006, American heart journal.

[156]  S. Themistoclakis,et al.  Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. , 2006, Heart rhythm.

[157]  Lippincott Williams Wilkins,et al.  ACC/AHA/SCAI Practice Guidelines, February 21, 2006 , 2006 .

[158]  I. Palacios,et al.  Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. , 2006, The American journal of cardiology.

[159]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[160]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Journal of the American College of Cardiology.

[161]  Bruce D. Johnson,et al.  Left atrial index is a predictor of exercise capacity in patients with hypertrophic cardiomyopathy. , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[162]  M. Gold,et al.  Sustained Ventricular Tachycardia Following Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy , 2005, Pacing and clinical electrophysiology : PACE.

[163]  D. Holmes,et al.  Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[164]  Harry Rakowski,et al.  Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[165]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[166]  Robert G. Hauser,et al.  Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.

[167]  J. Towbin,et al.  Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children , 2005, Circulation.

[168]  Christine E Seidman,et al.  The genetic basis for cardiac remodeling. , 2005, Annual review of genomics and human genetics.

[169]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[170]  S. Nagueh,et al.  Prevention of Cardiac Hypertrophy by Atorvastatin in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2005, Circulation research.

[171]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[172]  P. Boekstegers,et al.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. , 2005, Zeitschrift fur Kardiologie.

[173]  B. Maron,et al.  Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. , 2005, Heart rhythm.

[174]  P. Serruys,et al.  Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy , 2005, International journal of cardiovascular interventions.

[175]  W. Williams,et al.  Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. , 2005, The Journal of thoracic and cardiovascular surgery.

[176]  M. Götte,et al.  Early Onset and Progression of Left Ventricular Remodeling After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy , 2005, Circulation.

[177]  E. Vallejo,et al.  Myocardial perfusion SPECT imaging in patients with myocardial bridging , 2005, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[178]  W. Williams,et al.  Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy , 2005, Circulation.

[179]  B. Maron,et al.  Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[180]  J. Towbin,et al.  Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. , 2005, Journal of the American College of Cardiology.

[181]  H. Kuhn,et al.  Transcoronary Ablation of Septal Hypertrophy Does Not Alter ICD Intervention Rates in High Risk Patients with Hypertrophic Obstructive Cardiomyopathy , 2005, Pacing and clinical electrophysiology : PACE.

[182]  B. Maron,et al.  Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[183]  S. Nagueh,et al.  A prospective follow‐up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy—The baylor experience (1996–2002) , 2005, Clinical cardiology.

[184]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[185]  R. Falk,et al.  Cardiovascular magnetic resonance in cardiac amyloidosis. , 2005, Circulation.

[186]  P. Dimitrow,et al.  Echocardiographic risk factors predisposing to sudden cardiac death in hypertrophic cardiomyopathy , 2004, Heart.

[187]  S. Ernst,et al.  Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. , 2005, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[188]  A. Tajik,et al.  Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. , 2004, Journal of the American College of Cardiology.

[189]  Dick M. Goedhart,et al.  Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. , 2004, Journal of the American College of Cardiology.

[190]  T. Kato,et al.  Discrimination of Nonobstructive Hypertrophic Cardiomyopathy From Hypertensive Left Ventricular Hypertrophy on the Basis of Strain Rate Imaging by Tissue Doppler Ultrasonography , 2004, Circulation.

[191]  J. Ross,et al.  Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[192]  Barry J Maron,et al.  Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[193]  B. Gersh,et al.  The case for surgery in obstructive hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[194]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[195]  S. Kimber,et al.  Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. , 2004, Heart rhythm.

[196]  T. Ports,et al.  Ventricular tachycardia complicating alcohol septal ablation. , 2004, The New England journal of medicine.

[197]  G. Boriani,et al.  Prevention of Sudden Death in Hypertrophic Cardiomyopathy: But Which Defibrillator for Which Patient? , 2004, Circulation.

[198]  D. Fassbender,et al.  Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. , 2004, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[199]  J. Belmont,et al.  Clinical Spectrum, Morbidity, and Mortality in 113 Pediatric Patients With Mitochondrial Disease , 2004, Pediatrics.

[200]  M. Chiariello,et al.  Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[201]  K. Offit,et al.  The "duty to warn" a patient's family members about hereditary disease risks. , 2004, JAMA.

[202]  Y. Birnbaum,et al.  Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. , 2004, The American journal of the medical sciences.

[203]  M. Russo,et al.  Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy , 2004, Circulation.

[204]  A. Tajik,et al.  Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[205]  Michael J Ackerman,et al.  Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. , 2004, Circulation.

[206]  D. Pennell,et al.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography , 2004, Heart.

[207]  H. Kuhn,et al.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients , 2004, Heart.

[208]  F. T. ten Cate,et al.  Permanent pacing for complete atrioventricular block after nonsurgical (alcohol) septal reduction in patients with obstructive hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[209]  B. Maron,et al.  Pilots, hypertrophic cardiomyopathy, and issues of aviation and public safety. , 2004, The American journal of cardiology.

[210]  B. Maron,et al.  Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. , 2004, Journal of Thoracic and Cardiovascular Surgery.

[211]  N. Smedira,et al.  Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[212]  N. Smedira,et al.  Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. , 2004, The American journal of cardiology.

[213]  A. van Rossum,et al.  Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. , 2004, Journal of the American College of Cardiology.

[214]  B. Maron,et al.  From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy , 2003, Heart.

[215]  K. Schenck-Gustafsson,et al.  Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans , 1992, Cardiovascular Drugs and Therapy.

[216]  R. Hui,et al.  Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. , 2004, The American journal of medicine.

[217]  B. Maron.  Hypertrophic cardiomyopathy: an important global disease. , 2004, The American journal of medicine.

[218]  D. Holmes,et al.  Clinical practice. Hypertrophic obstructive cardiomyopathy. , 2004, The New England journal of medicine.

[219]  Maurizio Schiavon,et al.  Does sports activity enhance the risk of sudden death in adolescents and young adults? , 2003, Journal of the American College of Cardiology.

[220]  D. Pennell,et al.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. , 2003, European heart journal.

[221]  A. Tajik,et al.  Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease , 2003, Circulation.

[222]  H. Rakowski,et al.  Mutations of the β myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis , 2003 .

[223]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[224]  I. Olivotto,et al.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[225]  A. Tajik,et al.  Myocardial bridging in adult patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[226]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy with survival to advanced age. , 2003, Journal of the American College of Cardiology.

[227]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[228]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[229]  M. Quiñones,et al.  Tissue Doppler Imaging Predicts the Development of Hypertrophic Cardiomyopathy in Subjects With Subclinical Disease , 2003, Circulation.

[230]  Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. , 2003, Journal of the American College of Cardiology.

[231]  B. Maron,et al.  Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy. , 2003, The American journal of cardiology.

[232]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[233]  K. P. Carney,et al.  Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[234]  Jean-Claude Tardif,et al.  Symptomatic myocardial bridges: overview of ischemic mechanisms and current diagnostic and treatment strategies. , 2003, Journal of the American College of Cardiology.

[235]  M. Sherrid,et al.  Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. , 2003, The Annals of thoracic surgery.

[236]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[237]  Iacopo Olivotto,et al.  Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[238]  L. McLain,et al.  Sudden death in young athletes. , 2003, Pediatric annals.

[239]  E. D. Wigle,et al.  Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy , 2003 .

[240]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[241]  C. Autore,et al.  Risk associated with pregnancy in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[242]  M. S. Hamid,et al.  Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. , 2002, European heart journal.

[243]  H. Kuhn,et al.  Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions , 2002, Circulation.

[244]  M. Quiñones,et al.  Acute Effect of Nonsurgical Septal Reduction Therapy on Regional Left Ventricular Asynchrony in Patients With Hypertrophic Obstructive Cardiomyopathy , 2002, Circulation.

[245]  M. Chiariello,et al.  Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[246]  S. Solomon,et al.  Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy , 2002, Circulation.

[247]  A. Tajik,et al.  Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. , 2002, Journal of the American College of Cardiology.

[248]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[249]  M. Eriksson,et al.  Long-term outcome in patients with apical hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[250]  E. Behr,et al.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death , 2002, Heart.

[251]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[252]  B. Gersh,et al.  Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers , 2002 .

[253]  J. Schmitt,et al.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.

[254]  A. Tajik,et al.  Prevalence and Severity of “Benign” Mutations in the β-Myosin Heavy Chain, Cardiac Troponin T, and α-Tropomyosin Genes in Hypertrophic Cardiomyopathy , 2002, Circulation.

[255]  N. Smedira,et al.  Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. , 2002, Journal of the American College of Cardiology.

[256]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[257]  S. Ommen,et al.  Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[258]  B. Maron,et al.  The Electrocardiogram as a Diagnostic Tool for Hypertrophic Cardiomyopathy: Revisited , 2001, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[259]  J. Plana,et al.  Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. , 2001, The American journal of cardiology.

[260]  W. Stevenson,et al.  Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. , 2001, JAMA.

[261]  H Niimura,et al.  Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. , 2001, Journal of the American College of Cardiology.

[262]  M. Quiñones,et al.  Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[263]  Y. Doi,et al.  Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation. , 2001, Journal of cardiology.

[264]  S. Nagueh,et al.  Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy , 2001, Circulation.

[265]  H. Seggewiss.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy , 2001, Current cardiology reports.

[266]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[267]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[268]  C. Schmitt,et al.  Do Current Dual Chamber Cardioverter Defibrillators Have Advantages Over Conventional Single Chamber Cardioverter Defibrillators in Reducing Inappropriate Therapies? A Randomized, Prospective Study , 2001, Journal of cardiovascular electrophysiology.

[269]  S. Nagueh,et al.  Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[270]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[271]  W. Williams,et al.  Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. , 2000, Journal of the American College of Cardiology.

[272]  L. Fananapazir,et al.  Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. , 2000, Journal of the American College of Cardiology.

[273]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[274]  J. Seidman,et al.  Homozygous Mutation in Cardiac Troponin T: Implications for Hypertrophic Cardiomyopathy , 2000, Circulation.

[275]  M. Sherrid,et al.  Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. , 2000, Journal of the American College of Cardiology.

[276]  J. K. Dunn,et al.  Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. , 2000, Journal of the American College of Cardiology.

[277]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[278]  W. Morrow,et al.  Cardiomyopathy and heart transplantation in children , 2000, Current opinion in cardiology.

[279]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[280]  N. Lakkis.  New treatment methods for patients with hypertrophic obstructive cardiomyopathy , 2000, Current opinion in cardiology.

[281]  L. Faber,et al.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients , 2000, Heart.

[282]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[283]  A. Tajik,et al.  Dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy: a clinical perspective in 2000. , 2000, Mayo Clinic proceedings.

[284]  S. Ommen,et al.  Dynamic left ventricular outflow tract obstruction in acute coronary syndromes: an important cause of new systolic murmur and cardiogenic shock. , 2000, Mayo Clinic proceedings.

[285]  O. Schober,et al.  Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. , 1999, European heart journal.

[286]  L. Al-Jader.  Objectives of genetic counselling: differing views of purchasers, providers and users. , 1999, Journal of public health medicine.

[287]  H. Kuhn,et al.  Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. , 1999, European heart journal.

[288]  U. Gleichmann,et al.  Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[289]  K. Borisov,et al.  Management of Symptomatic Hypertrophic Obstructive Cardiomyopathy - Long-Term Results after Surgical Therapy , 1999, The Thoracic and cardiovascular surgeon.

[290]  A. Tajik,et al.  [Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy. A comparison of objective hemodynamic and exercise end points]. , 1999, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[291]  E. Aliot,et al.  Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing In Cardiomyopathy. , 1999, European heart journal.

[292]  M. Josephson,et al.  Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). , 1999, Circulation.

[293]  B. Maron,et al.  Hypertrophic Cardiomyopathy Prognostic Value of Systemic Blood Pressure Response During Exercise in a Community-Based Patient Population With Hypertrophic Cardiomyopathy , 2016 .

[294]  B. Maron,et al.  Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. , 1999, Journal of the American College of Cardiology.

[295]  P. Elliott,et al.  Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[296]  L. Rydén,et al.  Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. , 1999, The American journal of cardiology.

[297]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. , 1999, JAMA.

[298]  Seung‐Jung Park,et al.  Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. , 1998, The American journal of cardiology.

[299]  B. Maron,et al.  Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. , 1998, Circulation.

[300]  H. Sugihara,et al.  Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy , 1998, Annals of nuclear medicine.

[301]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[302]  M. Verani,et al.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. , 1998, Circulation.

[303]  B. McCrindle,et al.  Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death. , 1998, The New England journal of medicine.

[304]  T. Imaizumi,et al.  Predictors of sudden cardiac death in hypertrophic cardiomyopathy. , 1998, The American journal of cardiology.

[305]  Z. Kornacewicz-Jach,et al.  Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy , 1998, Heart.

[306]  D. Corrado,et al.  Screening for hypertrophic cardiomyopathy in young athletes. , 1998, The New England journal of medicine.

[307]  M. Verani,et al.  Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[308]  B. Maron,et al.  Implications of left ventricular remodeling in hypertrophic cardiomyopathy. , 1998, The American journal of cardiology.

[309]  Sherrid.  Dynamic Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy Revisited: Significance, Pathogenesis, and Treatment. , 1998, Cardiology in review.

[310]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[311]  B. Maron,et al.  Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population , 1998, Heart.

[312]  T. Meitinger,et al.  A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genes , 1998, Human Genetics.

[313]  P. Grayburn,et al.  Spontaneous Variability of Left Ventricular Outflow Tract Gradient in Hypertrophic Obstructive Cardiomyopathy , 1998, Circulation.

[314]  M. Sherrid,et al.  Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. , 1998, Circulation.

[315]  W. Mckenna,et al.  Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. , 1997, Circulation.

[316]  S. Michie,et al.  Information recall in genetic counselling: a pilot study of its assessment. , 1997, Patient education and counseling.

[317]  W. Mckenna,et al.  Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. , 1997, European heart journal.

[318]  L. Rydén,et al.  Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. , 1997, European heart journal.

[319]  Criley Jm.  Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy. , 1997 .

[320]  H. Watkins,et al.  Sudden death due to troponin T mutations. , 1997, Journal of the American College of Cardiology.

[321]  A. Tajik,et al.  Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. , 1997, Journal of the American College of Cardiology.

[322]  J. Criley.  Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy. , 1997, Journal of the American College of Cardiology.

[323]  C. Semsarian,et al.  Sudden cardiac death in familial hypertrophic cardiomyopathy: Are “benign” mutations really benign? , 1997, Pathology.

[324]  G. Danielson,et al.  Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. , 1996, The Journal of thoracic and cardiovascular surgery.

[325]  S. Lipshultz,et al.  Clinical approach to genetic cardiomyopathy in children. , 1996, Circulation.

[326]  A. Tajik,et al.  Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. , 1996, Circulation.

[327]  M. Chiariello,et al.  Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. , 1996, The American journal of cardiology.

[328]  F O Mueller,et al.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. , 1996, JAMA.

[329]  P. Hanrath,et al.  Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous beta-blocker medication. , 1996, Journal of the American College of Cardiology.

[330]  K. Bailey,et al.  Hypertrophic obstructive cardiomyopathy: preoperative echocardiographic predictors of outcome after septal myectomy. , 1996, Journal of the American College of Cardiology.

[331]  L. Rydén,et al.  Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy. , 1996, Journal of the American College of Cardiology.

[332]  R. Robbins,et al.  Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. , 1996, The Journal of thoracic and cardiovascular surgery.

[333]  A. Tajik,et al.  Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. , 1996, Journal of the American College of Cardiology.

[334]  A. Camm,et al.  DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. , 1996, Heart.

[335]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[336]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[337]  F. Flachskampf,et al.  Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. , 1995, Circulation.

[338]  K. Bailey,et al.  Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. , 1995, Circulation.

[339]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[340]  S. Nakatani,et al.  Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. , 1995, Journal of the American College of Cardiology.

[341]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[342]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[343]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[344]  B. Maron,et al.  Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. , 1995, Circulation.

[345]  C. Autore,et al.  Prognosis of Asymptomatic Patients With Hypertrophic Cardiomyopathy and Nonsustained Ventricular Tachycardia , 1994, Circulation.

[346]  D Tripodi,et al.  Long‐term Results of Dual‐Chamber (DDD) Pacing in Obstructive Hypertrophic Cardiomyopathy: Evidence for Progressive Symptomatic and Hemodynamic Improvement and Reduction of Left Ventricular Hypertrophy , 1994, Circulation.

[347]  D Tripodi,et al.  Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy. , 1994, The American journal of cardiology.

[348]  S. Reith,et al.  Surgical correction of hypertrophic obstructive cardiomyopathy with combined myectomy, mobilisation and partial excision of the papillary muscles. , 1994, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[349]  S. Solomon,et al.  Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. , 1994, The Journal of clinical investigation.

[350]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[351]  D. Kass,et al.  Diastolic Compliance of Hypertrophied Ventricle Is Not Acutely Altered by Pharmacologic Agents Influencing Active Processes , 1993, Annals of Internal Medicine.

[352]  M. Sherrid,et al.  An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[353]  V. Dilsizian,et al.  Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[354]  M A Proschan,et al.  Echocardiographic Assessment of Mitral Valve Size in Obstructive Hypertrophic Cardiomyopathy Anatomic Validation From Mitral Valve Specimen , 1993, Circulation.

[355]  B. Kimball,et al.  Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. , 1993, American heart journal.

[356]  W. Chan,et al.  A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[357]  J. Wodniecki,et al.  Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. , 1993, Cardiology.

[358]  J. Bouret,et al.  [Obstructive myocardiopathy and pregnancy]. , 1993, Journal de gynecologie, obstetrique et biologie de la reproduction.

[359]  E. Rosenkranz,et al.  Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. , 1992, Journal of the American College of Cardiology.

[360]  J. Seidman,et al.  Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. , 1992, The Journal of clinical investigation.

[361]  W. Williams,et al.  Surgical intervention and support for cardiomyopathies of childhood , 1992 .

[362]  L. Cohn,et al.  Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. , 1992, The American journal of cardiology.

[363]  S. Epstein,et al.  Prognostic Determinants in Hypertrophic Cardiomyopathy: Prospective Evaluation of a Therapeutic Strategy Based on Clinical, Holter, Hemodynamic, and Electrophysiological Findings , 1992, Circulation.

[364]  W. Williams,et al.  Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. , 1992, Journal of the American College of Cardiology.

[365]  A. Tajik,et al.  Mitral regurgitation due to ruptured chordae tendineae in patients with hypertrophic obstructive cardiomyopathy. , 1992, Journal of the American College of Cardiology.

[366]  D Tripodi,et al.  Impact of Dual‐Chamber Permanent Pacing in Patients With Obstructive Hypertrophic Cardiomyopathy With Symptoms Refractory to Verapamil and β‐Adrenergic Blocker Therapy , 1992, Circulation.

[367]  Lukas Kappenberger,et al.  Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy , 1992, The Lancet.

[368]  W. Roberts,et al.  Diversity of Structural Mitral Valve Alterations in Hypertrophic Cardiomyopathy , 1992, Circulation.

[369]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[370]  V. Dilsizian,et al.  Impact of Surgical Relief of Outflow Obstruction on Thallium Perfusion Abnormalities in Hypertrophic Cardiomyopathy , 1992, Circulation.

[371]  B. Maron,et al.  Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. , 1992, Journal of the American College of Cardiology.

[372]  J. Seidman,et al.  Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. , 1991, The New England journal of medicine.

[373]  W. Roberts,et al.  Anomalous Insertion of Papillary Muscle Directly Into Anterior Mitral Leaflet in Hypertrophic Cardiomyopathy: Significance in Producing Left Ventricular Outflow Obstruction , 1991, Circulation.

[374]  A. Quyyumi,et al.  Myocardial Metabolic, Hemodynamic, and Electrocardiographic Significance of Reversible Thallium‐201 Abnormalities in Hypertrophic Cardiomyopathy , 1991, Circulation.

[375]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[376]  A. L'Abbate,et al.  Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. , 1991, Journal of the American College of Cardiology.

[377]  M. Frenneaux,et al.  Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. , 1990, Circulation.

[378]  M. Frenneaux,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. , 1990, Journal of the American College of Cardiology.

[379]  G. Kay,et al.  Rate-modulated cardiac pacing based on transthoracic impedance measurements of minute ventilation: correlation with exercise gas exchange. , 1989, Journal of the American College of Cardiology.

[380]  H. Schaff,et al.  Results of operation for hypertrophic obstructive cardiomyopathy in children and adults less than 40 years of age. , 1989, Circulation.

[381]  B. Maron,et al.  Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. , 1989, The American journal of cardiology.

[382]  B. Maron,et al.  Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. , 1989, Journal of the American College of Cardiology.

[383]  R. Bonow,et al.  Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. , 1989, Circulation.

[384]  R. Bonow,et al.  Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. , 1989, Circulation.

[385]  M. Z. Berisso,et al.  Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. , 1989, The New England journal of medicine.

[386]  B. Healy,et al.  Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. , 1989, Circulation.

[387]  B. Maron,et al.  Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy. , 1989, The Annals of thoracic surgery.

[388]  B. Kimball,et al.  Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. , 1988, The American journal of cardiology.

[389]  C. Pollick.  Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration. , 1988, The American journal of cardiology.

[390]  M. Sherrid,et al.  Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. , 1988, The American journal of cardiology.

[391]  Z. Krajcer,et al.  Mitral valve replacement and septal myomectomy in hypertrophic cardiomyopathy. Ten-year follow-up in 80 patients. , 1988, Circulation.

[392]  B. Maron,et al.  Current operative treatment of obstructive hypertrophic cardiomyopathy. , 1988, Circulation.

[393]  K. McDonald,et al.  Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. , 1988, European heart journal.

[394]  R L Popp,et al.  Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. , 1988, Journal of the American College of Cardiology.

[395]  S. Larson,et al.  Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. , 1987, Circulation.

[396]  W. Williams,et al.  Results of surgery for hypertrophic obstructive cardiomyopathy. , 1987, Circulation.

[397]  R. Bonow,et al.  Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. , 1987, Journal of the American College of Cardiology.

[398]  W. Roberts,et al.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.

[399]  R. Siegel,et al.  Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy. , 1986, Postgraduate medical journal.

[400]  W. Mckenna,et al.  Amiodarone dose titration: a method to minimise side effects during long term therapy. , 1986, British journal of clinical practice. Supplement.

[401]  W. Roberts,et al.  Causes of sudden death in competitive athletes. , 1986, Journal of the American College of Cardiology.

[402]  R. Siegel,et al.  Has 'obstruction' hindered our understanding of hypertrophic cardiomyopathy? , 1985, Circulation.

[403]  Michael V. Green,et al.  Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. , 1985, Circulation.

[404]  A. Epeldegui,et al.  Myocardial bridging and hypertrophic cardiomyopathy: relief of ischemia by surgery. , 1985, International journal of cardiology.

[405]  W. Williams,et al.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. , 1985, Progress in cardiovascular diseases.

[406]  J. Dussaule,et al.  Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. , 1985, American heart journal.

[407]  R. Bonow,et al.  Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. , 1985, Circulation.

[408]  B. Maron,et al.  Morphologic determinants of hemodynamic state after ventricular septal myotomy-myectomy in patients with obstructive hypertrophic cardiomyopathy: M mode and two-dimensional echocardiographic assessment. , 1984, Circulation.

[409]  W. Mckenna,et al.  Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. , 1984, The American journal of cardiology.

[410]  W. E. Craig,et al.  Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: altered left ventricular loading or improved muscle inactivation? , 1983, Journal of the American College of Cardiology.

[411]  Michael V. Green,et al.  Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. , 1983, Circulation.

[412]  W. Roberts,et al.  Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. , 1983, Circulation.

[413]  R. Bonow,et al.  Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. , 1983, The American journal of cardiology.

[414]  L. Harris,et al.  Side Effects of Long-term Amiodarone Therapy , 1983, Circulation.

[415]  C. Pollick.  Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. , 1982, The New England journal of medicine.

[416]  J. Goodwin,et al.  Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. , 1982, British heart journal.

[417]  F. Morady,et al.  Drugs Five Years Later: Disopyramide , 1982 .

[418]  Michael V. Green,et al.  Effects of Verapamil on Left Ventricular Systolic Function and Diastolic Filling in Patients with Hypertrophic Cardiomyopathy , 1981, Circulation.

[419]  R. Bonow,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. , 1981, The American journal of cardiology.

[420]  J. Gottdiener,et al.  Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. , 1981, The American journal of cardiology.

[421]  S. Epstein,et al.  Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. , 1981, Circulation.

[422]  M. Wong,et al.  Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in systolic anterior motion of mitral valve. , 1981, The American journal of cardiology.

[423]  B. Maron,et al.  Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. , 1981, The American journal of cardiology.

[424]  W. Mckenna,et al.  Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. , 1981, The American journal of cardiology.

[425]  C. Robertson,et al.  Extreme tachycardia complicating the use of disopyramide in atrial flutter. , 1980, British heart journal.

[426]  D. Rowbotham,et al.  Potentially dangerous effect of disopyramide on atrioventricular conduction in a patient on digitalis. , 1980, British medical journal.

[427]  B. Maron,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. , 1979, Circulation.

[428]  B. Maron,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. , 1979, Circulation.

[429]  B. Maron,et al.  Hypertrophic cardiomyopathy: a discussion of nomenclature. , 1979, The American journal of cardiology.

[430]  A. Abdulla,et al.  Long-term medical management of hypertrophic obstructive cardiomyopathy. , 1978, The American journal of cardiology.

[431]  E. V. Vaughan Williams,et al.  Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods. , 1977, British heart journal.

[432]  R. Swanton,et al.  Hemodynamic studies of beta blockade in hypertrophic obstructive cardiomyopathy. , 1977, European journal of cardiology.

[433]  R. Falicov,et al.  Mid-ventricular obstruction: a variant of obstructive cardiomyopathy. , 1976, The American journal of cardiology.

[434]  P. Lucchelli,et al.  Antidepressant Treatment with Maprotiline* in the Management of Emotional Disturbances in Patients with Acute Myocardial Infarction: A Controlled Study , 1976, The Journal of international medical research.

[435]  G. Jensen,et al.  Circulatory effects of intravenous disopyramide in heart failure. , 1976, The Journal of international medical research.

[436]  Wigle Ed,et al.  Medical and surgical treatment of the cardiomyopathies. , 1974 .

[437]  E. Wigle,et al.  Medical and Surgical Treatment of the Cardiomyopathies , 1974, Circulation research.

[438]  E. W. Hancock,et al.  Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. , 1973, The American journal of cardiology.

[439]  R. Gramiak,et al.  Long-term propranolol therapy in muscular subaortic stenosis. , 1970, British heart journal.

[440]  E. Wigle,et al.  Mitral regurgitation in muscular subaortic stenosis. , 1969, The American journal of cardiology.

[441]  E. W. Hancock,et al.  Muscular Subaortic Stenosis: Prevention of Outflow Obstruction with Propranolol , 1968, Circulation.

[442]  E. Braunwald,et al.  Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta‐Adrenergic Blockade , 1967, Circulation.

[443]  R. Nishimura,et al.  Hypertrophic Obstructive Cardiomyopathy , 2009 .

[444]  E. Sonnenblick,et al.  Studies on Digitalis: XV. Effects of Cardiac Glycosides on Myocardial Force‐Velocity Relations in the Nonfailing Human Heart , 1966, Circulation.

[445]  E. Wigle,et al.  MUSCULAR SUBAORTIC STENOSIS; THE INTERRELATION OF WALL TENSION, OUTFLOW TRACT "DISTENDING PRESSURE" AND ORIFICE RADIUS. , 1965, The American journal of cardiology.

[446]  D. E. Cobb,et al.  Idiopathic Hypertrophic Subaortic Stenosis: III. Intraoperative Studies of the Mechanism of Obstruction and Its Hemodynamic Consequences , 1964 .

[447]  C. Lambrew,et al.  Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients , 1964, Circulation.

[448]  J. Ross,et al.  Effects of Beta Adrenergic Blockade on the Circulation, with Particular Reference to Observations in Patients with Hypertrophic Subaortic Stenosis , 1964, Circulation.

[449]  R. Whalen,et al.  Demonstration of the dynamic nature of idiopathic hypertrophic subaortic stenosis. , 1963, The American journal of cardiology.

[450]  N. Krasnow,et al.  Reversible obstruction of the ventricular outflow tract. , 1963, The American journal of cardiology.

[451]  E. Braunwald,et al.  Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. , 1962, The American journal of cardiology.

[452]  E. Braunwald,et al.  Studies on Digitalis: V. Comparison of the Effects of Ouabain on Left Ventricular Dynamics in Valvular Aortic Stenosis and Hypertrophic Subaortic Stenosis , 1962, Circulation.

[453]  F. Ellis,et al.  Surgical Relief of Diffuse Subvalvular Aortic Stenosis , 1961, Circulation.

[454]  E. Brockenbrough,et al.  Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. , 1961, Annals of surgery.

[455]  E. Braunwald,et al.  STUDIES ON DIGITALIS. IV. OBSERVATIONS IN MAN ON THE EFFECTS OF DIGITALIS PREPARATIONS ON THE CONTRACTILITY OF THE NON-FAILING HEART AND ON TOTAL VASCULAR RESISTANCE. , 1961, The Journal of clinical investigation.

[456]  R. Brock.  Functional obstruction of the left ventricle (acquired aortic subvalvar stenosis). , 1959, Guy's Hospital reports.

[457]  D TEARE,et al.  ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.